MDNA News and Press, Medicenna Therapeutics Corp. From 09/08/22

TORONTO and HOUSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced that the Company management and scientific teams w...

Medicenna Therapeutics Corp. (MDNA) Q1 2023 Earnings Conference Call August 15, 2022, 08:30 AM ET Company Participants Dan Ferry - IR, LifeSci Advisors Fahar Merchant - President & CEO Liz Williams - CFO Conference Call Participants Matt Biegler -...

Medicenna Therapeutics press release ( NASDAQ: MDNA ): Q1 GAAP EPS of -$0.07 in-line. Medicenna had cash, cash equivalents, and marketable securities of $19.3 million at June 30, 2022, compared to $20.5 million at March 31, 2022. For further details see: Medicenn...

-- Extended Cash Runway Into 2024 With US$20 Million Raise To Complete Phase 1/2 ABILITY Study And Advance Pipeline -- New MDNA11 Data From Dose Escalation in ABILITY Study Shows Tumor Control In Four Of Ten Evaluable Patients Including Unconfirmed Partial Response In Pancreatic...

TORONTO and HOUSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA, TSX: MDNA), a clinical stage immunotherapy company, is pleased to announce the closing of its previously announced marketed unde...

Gainers: BBQ Holdings ( BBQ ) +46% . Verona Pharma ( VRNA ) +41% . Mersana Therapeutics ( MRSN ) +31% . SAI.TECH Global ( SAI ) +30% . Atara Biotherapeutics ( ATRA ) +28% . PubMatic ( PUBM ) +24% . RumbleON ( RM...

Gainers: Verona Pharma VRNA +87% . Mersana Therapeutics ( MRSN ) +38% . GoodRx Holdings ( GDRX ) +19% . Atara Biotherapeutics ( ATRA ) +22% . Heron Therapeutics HRTX +16% . Losers: CorMedix ( CRMD ) -56% . Qu...

Medicenna Therapeutics ( NASDAQ: MDNA ) on Tuesday has priced its 13.33M units offering to $1.50 each, resulting in gross proceeds of ~$20M. Each unit will be comprised of 1 common share and 1 share purchase warrant exercisable to purchase additional share at a price ...

TORONTO and HOUSTON, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA, TSX: MDNA), a clinical stage immunotherapy company, announced today that it has priced its previously-announced marketed underwr...

CorMedix CRMD -61% after FDA again rejects CorMedix's application for lead candidate DefenCath . Turtle Beach HEAR -32% on Q2 earnings miss . Novavax NVAX -31% on Q2 earnings release . Medicenna Therapeutics MDNA -29% on launch of units offeri...